Cargando…

Alemtuzumab: a review of efficacy and risks in the treatment of relapsing remitting multiple sclerosis

Alemtuzumab is a selective humanized monoclonal antibody directed against the CD52 antigen, and has been found to be a powerful treatment for relapsing remitting multiple sclerosis. Alemtuzumab demonstrated high efficacy in several clinical studies. The risk of relapse and sustained accumulation of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Guarnera, Cristina, Bramanti, Placido, Mazzon, Emanuela
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2017
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5522829/ https://www.ncbi.nlm.nih.gov/pubmed/28761351 http://dx.doi.org/10.2147/TCRM.S134398

Ejemplares similares

Comparison of efficacy and safety of oral agents for the treatment of relapsing–remitting multiple sclerosis
por: Guarnera, Cristina, et al.
Publicado: (2017)

Alemtuzumab: evidence for its potential in relapsing—remitting multiple sclerosis
por: Brown, JWL, et al.
Publicado: (2013)

Alemtuzumab improves contrast sensitivity in patients with relapsing–remitting multiple sclerosis
por: Graves, Jennifer, et al.
Publicado: (2013)

Alemtuzumab: A new therapy for active relapsing–remitting multiple sclerosis
por: Hartung, Hans-Peter, et al.
Publicado: (2015)

The use of alemtuzumab in patients with relapsing-remitting multiple sclerosis: the Gulf perspective
por: Alroughani, Raed, et al.
Publicado: (2020)

Identification of CD4(+) T cell biomarkers for predicting the response of patients with relapsing-remitting multiple sclerosis to natalizumab treatment
por: Fagone, Paolo, et al.
Publicado: (2019)

Repopulation of T, B, and NK cells following alemtuzumab treatment in relapsing-remitting multiple sclerosis
por: Gilmore, Wendy, et al.
Publicado: (2020)

Immune Regulatory Cell Bias Following Alemtuzumab Treatment in Relapsing-Remitting Multiple Sclerosis
por: Kashani, Nicole, et al.
Publicado: (2021)

A multicentric pharmacovigilance study: collection and analysis of adverse drug reactions in relapsing-remitting multiple sclerosis patients
por: Gugliandolo, Agnese, et al.
Publicado: (2018)

Microscopic polyangiitis after alemtuzumab treatment in relapsing-remitting MS
por: Sauer, Eva-Maria, et al.
Publicado: (2018)

Autologous haematopoietic stem cell transplantation compared with alemtuzumab for relapsing–remitting multiple sclerosis: an observational study
por: Zhukovsky, Christina, et al.
Publicado: (2021)

Alemtuzumab‐induced petechiae and epistaxis in a patient with relapsing–remitting multiple sclerosis: A case report
por: Mahmoudi, Farhad, et al.
Publicado: (2023)

Proportion of alemtuzumab-treated patients converting from relapsing-remitting multiple sclerosis to secondary progressive multiple sclerosis over 6 years
por: Horáková, Dana, et al.
Publicado: (2020)

Safety and efficacy with alemtuzumab over 13 years in relapsing-remitting multiple sclerosis: final results from the open-label TOPAZ study
por: Coles, Alasdair J., et al.
Publicado: (2023)

Alemtuzumab in the long-term treatment of relapsing-remitting multiple sclerosis: an update on the clinical trial evidence and data from the real world
por: Ziemssen, Tjalf, et al.
Publicado: (2017)

Twin pregnancy outcome following teriflunomide treatment in a relapsing-remitting multiple sclerosis patient: A case report
por: D’Aleo, Giangaetano, et al.
Publicado: (2020)

The Role of Cytotoxic T-Lymphocyte Antigen 4 in the Pathogenesis of Multiple Sclerosis
por: Basile, Maria Sofia, et al.
Publicado: (2022)

The Gut Microbiota in Multiple Sclerosis: An Overview of Clinical Trials
por: Schepici, Giovanni, et al.
Publicado: (2019)

Mesenchymal Stem Cells in Multiple Sclerosis: Recent Evidence from Pre-Clinical to Clinical Studies
por: Gugliandolo, Agnese, et al.
Publicado: (2020)

Acute effects of alemtuzumab infusion in patients with active relapsing-remitting MS
por: Thomas, Katja, et al.
Publicado: (2016)

Alemtuzumab improves preexisting disability in active relapsing-remitting MS patients
por: Giovannoni, Gavin, et al.
Publicado: (2016)

Risk-benefit considerations in the treatment of relapsing-remitting multiple sclerosis
por: Lugaresi, Alessandra, et al.
Publicado: (2013)

Alemtuzumab in the treatment of multiple sclerosis
por: Fernandez, Óscar
Publicado: (2014)

Alemtuzumab for the treatment of multiple sclerosis
por: Willis, Mark D, et al.
Publicado: (2015)

Efficacy of alemtuzumab over 6 years in relapsing–remitting multiple sclerosis patients who relapsed between courses 1 and 2: Post hoc analysis of the CARE-MS studies
por: Van Wijmeersch, Bart, et al.
Publicado: (2019)

Intractable and highly active relapsing multiple sclerosis – role of alemtuzumab
por: Dubey, Divyanshu, et al.
Publicado: (2015)

The role of autoimmune antibodies to predict secondary autoimmunity in patients with relapsing-remitting multiple sclerosis treated with alemtuzumab: A nationwide prospective survey
por: Sandgren, Sofia, et al.
Publicado: (2023)

Understanding the positive benefit:risk profile of alemtuzumab in relapsing multiple sclerosis: perspectives from the Alemtuzumab Clinical Development Program
por: Havrdova, Eva, et al.
Publicado: (2017)

Efficacy and Safety of Alemtuzumab in Patients of African Descent with Relapsing-Remitting Multiple Sclerosis: 8-Year Follow-up of CARE-MS I and II (TOPAZ Study)
por: Okai, Annette F., et al.
Publicado: (2019)

A Model-Based Economic Evaluation of Cladribine Versus Alemtuzumab, Ocrelizumab and Natalizumab for the Treatment of Relapsing-Remitting Multiple Sclerosis with High Disease Activity in Chile
por: Espinoza, Manuel Antonio, et al.
Publicado: (2021)

Clinical efficacy, safety, and tolerability of fingolimod for the treatment of relapsing-remitting multiple sclerosis
por: Gajofatto, Alberto, et al.
Publicado: (2015)

High-Efficacy Therapies for Treatment-Naïve Individuals with Relapsing–Remitting Multiple Sclerosis
por: Freeman, Léorah, et al.
Publicado: (2022)

Alemtuzumab for Multiple Sclerosis
por: Willis, Mark D., et al.
Publicado: (2016)

Could the Heat Shock Proteins 70 Family Members Exacerbate the Immune Response in Multiple Sclerosis? An in Silico Study
por: Chiricosta, Luigi, et al.
Publicado: (2020)

Comparative efficacy of alemtuzumab and established treatment in the management of multiple sclerosis
por: Babij, Rachel, et al.
Publicado: (2015)

Postural Control in Relapsing-Remitting Multiple Sclerosis
por: Cusin, Flavia Salvaterra, et al.
Publicado: (2022)

Safety and Efficacy of Fingolimod in Iranian Patients with Relapsing-remitting Multiple Sclerosis
por: Yavari, Fatemeh, et al.
Publicado: (2021)

Topical moringin cream relieves neuropathic pain by suppression of inflammatory pathway and voltage-gated ion channels in murine model of multiple sclerosis
por: Giacoppo, Sabrina, et al.
Publicado: (2017)

Natalizumab is Effective for the Treatment of Relapsing-remitting Tumefactive Multiple Sclerosis
por: Nakamura, Masataka, et al.
Publicado: (2017)

Natalizumab: A new treatment for relapsing remitting multiple sclerosis
por: Hutchinson, Michael
Publicado: (2007)

Cannot write session to /tmp/vufind_sessions/sess_3esvsjkh1gpt6miol793t7d2ee